AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug development company, has launched predictBBB.ai(TM), a public AI module that predicts blood-brain barrier (BBB) permeability of small molecules with 94% accuracy, 95% sensitivity, and 89% specificity. Built on billions of molecular data points from Lantern’s proprietary data lake, the platform addresses the pharmaceutical challenge that only 2–6% of small molecules can cross the BBB. PredictBBB.ai(TM) ranks among the top performers on the Therapeutic Data Commons Leaderboard, leveraging synthetic data augmentation and advanced molecular representation to process compounds in real time. The launch comes as the BBB technologies market is projected to grow…